Cardiovascular risk factor(s) prevalence in Greek hypertensives. Effect of gender and age

Journal of Human Hypertension

Volumn 26, Issue 7, 2012, Pages 443-451

  Vyssoulis, G P ^a   Karpanou, E A ^b   Liakos, C I ^a   Kyvelou, S M G ^a   Tzamou, V E ^a   Michaelides, A P ^a   Triantafyllou, A I ^a   Spanos, P G ^a   Stefanadis, C I ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b ONASSIS CARDIAC SURGERY CENTER   (Greece)

Author keywords

arterial hypertension; blood pressure; cardiovascular risk; cardiovascular risk factors; cardiovascular risk scores

Indexed keywords

ADULT; AGE; AGED; CARDIOVASCULAR RISK; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; FRAMINGHAM RISK SCORE; GENDER; GLOMERULUS FILTRATION RATE; GREECE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART SCORE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OBESITY; PREVALENCE; PULSE PRESSURE; REVIEW; SMOKING;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; FEMALE; GLOMERULAR FILTRATION RATE; GREECE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 84863725831     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/jhh.2011.55     Document Type: Review

References (26)

1. Belletti DA, Zacker C, Wogen J. Effect of cardiometabolic risk factors on hypertension management: a cross-sectional study among 28 physician practices in the United States. Cardiovasc Diabetol 2010; 9: 7-18.
2. Kannel WB. Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: S3-S10.
3. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006; 295: 1549-1555.
4. Flegal KM, Graubard BI, Williamson DF, Gail MH. Excess deaths associated with underweight, overweight, and obesity. JAMA 2005; 293: 1861-1867.
5. Giles T, Aranda JM, Suh DC, Choi IS, Preblick R, Rocha R et al. Ethnic/racial variations in blood pressure awareness, treatment, and control. J Clin Hypertens 2007; 9: 345-354.
6. Ong KL, Tso AWK, Lam KSL, Cheung BMY. Gender differences in blood pressure control and cardiovascular risk factors in Americans with diagnosed hypertension. Hypertension 2008; 51: 1142-1148.
7. Sullivan PW, Ghushchyan V, Wyatt HR, Hill JO. The medical cost of cardiometabolic risk factor clusters in the United States. Obesity 2007; 15: 3150-3158.
8. Farsang C, Naditch-Brule L, Perlini S, Zidek W, Kjeldsen SE. Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Hum Hypertens 2009; 23(5): 316-324.
9. Williams JR. The declaration of Helsinki and public health. Bull World Health Organ 2008; 86(8): 650-652.
10. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
11. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-470.
12. Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH. International federation of clinical chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of international reference material. Clin Chem 1994; 40: 586-592.
13. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. Eur J Echocardiogr 2006; 7(2): 79-108.
14. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr JL et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
15. Mancia G, de Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.
16. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield M et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121-2158.
17. The Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
18. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA et al. 2010 ACCF/AHA Guidelines for assessment of cardiovascular risk in asymptomatic adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 2010; 56(25): e50-e103.
19. D'Agostino RB, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM et al. General cardiovascular risk profile for use in primary care: the framingham heart study. Circulation 2008; 117: 743-753.
20. Conroy RM, Pyörälä K, Fitzgerald A, Sans S, Menotti A, De Backer G et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003; 24: 987-1003.
21. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28(19): 2375-2414.
22. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
23. Pavlopoulos H, Nihoyannopoulos P. The constellation of hypertensive heart disease. Hellenic J Cardiol 2008; 49: 92-99.
24. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. European network for non-invasive investigation of large arteries: expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006; 21: 2588-2605.
25. Ganotakis ES, Mikhailidis DP, Vardas PE. Atrial fibrillation, inflammation and statins. Hellenic J Cardiol 2006; 2: 51-53.
26. Konstantopoulou AS, Papargyriou IK, Antoniadou ES, Konstantopoulou PS, Papadogiannis DE. Masked hypertension: a new entity under investigation. Hellenic J Cardiol 2006; 4: 232-235.